Results 191 to 200 of about 114,702 (262)

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case report. [PDF]

EJHaem
Nikkarinen A, Glimelius I.
europepmc   +1 more source

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

, 2018
Bartlett, Nancy L.
core   +1 more source

Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma. [PDF]

Front Cardiovasc Med
Du J, Chen ZY, Gu XR, Wang T, Huang ZF.
europepmc   +1 more source

A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. [PDF]

Sci Rep
Ding Y, Huang K, Sun C, Liu Z, Zhu J, Jiao X, Liao Y, Feng X, Guo J, Zhu C, Zhai Z, Xiong S.   +11 more
europepmc   +1 more source

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma [PDF]

, 2017

core   +1 more source

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.

JAMA Oncology, 2015
S. Fabbro, Sabrina M. Smith, J. Dubovsky, A. Gru, Jeffrey A Jones   +4 more
semanticscholar   +1 more source